Philip Bourne, UCSD to Present at Protein Interaction Conference, Oct 2013
Philip Bourne, AVC at UCSD Will Present at Protein Interaction Conference Oct 23-25, 2013, San Diego
San Diego, CA, August 23, 2013 --(PR.com)-- Philip Bourne, Associate Vice Chancellor for Innovation and Industrial Alliances, Professor of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego; Associate Director, RCSB Protein Data Bank; Founding Editor in Chief, PLOS Computational Biology; Co-founder, SciVee will give a Featured Presentation on “Accelerating Discovery in PPI's Through Open Science” at the Protein-Protein Interaction Conference to be held in San Diego, CA on October 23-25, 2013 by GTC.
The relatively new field of Protein-Protein Interaction (PPI) is experiencing fantastic growth in the field of drug discovery. The key concepts of PPI are to understand how proteins interact, to understand why inhibiting them is beneficial, and how to identify molecules that block the interactions as treatment strategies.
The Protein-Protein Interaction Conference will have sessions that cover novel techniques, new algorithms databases for PPIs, and potential druggable sites for disrupting protein-protein interactions. Attendees will gain an enhanced understanding of the molecular basis of peptide and protein aggregation and insights into the design of inhibitors of peptide and protein aggregation. Some focused topics we will discuss is how inhibiting PPIs can be a promising therapeutic target, PPI interactions within the TNF family, the first small-molecule inhibitors for the CD40–CD40L, and much more including the fundamental aspects of protein-protein interactions.
This conference is also part of the Protein Discovery Summit, which consists of this track and three other tracks:
I. Antibody and Protein Therapeutics
II. Protein Expression, Purification & Characterization
III. 2nd Protein Kinases and Drug Design
For more information, please visit www.gtcbio.com/ppi
The relatively new field of Protein-Protein Interaction (PPI) is experiencing fantastic growth in the field of drug discovery. The key concepts of PPI are to understand how proteins interact, to understand why inhibiting them is beneficial, and how to identify molecules that block the interactions as treatment strategies.
The Protein-Protein Interaction Conference will have sessions that cover novel techniques, new algorithms databases for PPIs, and potential druggable sites for disrupting protein-protein interactions. Attendees will gain an enhanced understanding of the molecular basis of peptide and protein aggregation and insights into the design of inhibitors of peptide and protein aggregation. Some focused topics we will discuss is how inhibiting PPIs can be a promising therapeutic target, PPI interactions within the TNF family, the first small-molecule inhibitors for the CD40–CD40L, and much more including the fundamental aspects of protein-protein interactions.
This conference is also part of the Protein Discovery Summit, which consists of this track and three other tracks:
I. Antibody and Protein Therapeutics
II. Protein Expression, Purification & Characterization
III. 2nd Protein Kinases and Drug Design
For more information, please visit www.gtcbio.com/ppi
Contact
GTC
Kristen Starkey
626-256-6405
http://www.gtcbio.com
635 W. Foothill Blvd.
Monrovia, CA 91016
fax: 626-466-4433
Contact
Kristen Starkey
626-256-6405
http://www.gtcbio.com
635 W. Foothill Blvd.
Monrovia, CA 91016
fax: 626-466-4433
Categories